Bristol Myers Squibb Vs. AbbVie Stock
Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...
Bristol-Myers wins FDA nod for first-of-its-kind antipsychotic
Bristol-Myers Squibb (BMY) stock rises as FDA approves Cobenfy as a ovel treatment for adults with the psychiatric disorder ...
Sell Rating on Bristol-Myers Squibb Amid Competitive Pressures and Pricing Concerns
In a report released yesterday, Carter Gould from Barclays maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), with ...
Bristol-Myers Squibb Company (BMY): Among the Dividend Giants with Lowest Short Interest in 2024
We recently compiled a list of the 8 Dividend Giants with Lowest Short Interest in 2024. In this article, we are going to ...
BioPharma Dive7h
Bristol Myers schizophrenia drug, the first of its kind, approved by FDA
In testing, Cobenfy eased schizophrenia symptoms without some of the disruptive side effects typical of existing drugs. The results have been met with excitement, as well as caution.
FiercePharma1d
Citing enrollment challenges, Bristol Myers and 2seventy scrap Abecma trial in first-line myeloma
Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma ...
Treasury15h
BMS Breaks Free from the Captivity of an Inefficient Insurance Structure
Congratulations to Bristol Myers Squibb on winning the 2024 Silver Alexander Hamilton Award in Operational Risk Management & ...
Petri Dish: 2seventy, BMS halt Phase 3 trial; Flagship spinout names CSO
Inc. and Bristol Myers Squibb halted a Phase 3 trial, the Healey-Driscoll administration has announced nearly $20 million in ...